ArticlePigment cell & melanoma research2012
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.
Article in Pigment cell & melanoma research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 208 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fractional Carbon Dioxide Laser Combined With Topical Corticosteroid and Narrow Band Ultraviolet B in Treatment of Stable Vitiligo.
Evaluation of Efficacy of Microneedling and Topical Methotrexate Versus Microneedling and Topical 5-flourouracil in Treatment of Vitillgo Patients
Assessment of Hypoxia Inducible Factor and Autophagy Related Genes in Patients With Non-Segmental Vitiligo
Who cites it
208 citing papers in PubMed, 5 syntheses or guidelines pooled it, 666 citations in OpenAlex.
- Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).The Journal of dermatology · 2026Guideline
- Regulatory T Cell Dysregulation in Vitiligo: A Meta-Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives.International journal of dermatology · 2025Pooled it
- Safety and efficacy of Simvastatin in the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials.Archives of dermatological research · 2025Pooled it
- Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.Annals of medicine · 2024Pooled it
- The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis.Lasers in medical science · 2021Pooled it
- Cryoblebbing with 5-fluorouracil versus cryoblebbing with melanocyte keratinocyte transplant procedure or cryoblebbing alone in treatment of stable vitiligo.Archives of dermatological research · 2025Trial
- Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.Archives of dermatological research · 2024Trial
- Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study.Scientific reports · 2024Trial
- Demographic factors associated with response to topical Jak inhibitors in a diverse vitiligo cohort.JID innovations : skin science from molecules to population health · 2026Article
- Personalized Approaches to Facial Vitiligo: A Comprehensive Review From Clinical Phenotypes to Novel Therapeutic Strategies.Annals of dermatology · 2026Review
- Vitiligo and Its Mimics in Childhood: A Diagnostic Framework for Hypopigmented Disorders.Annals of dermatology · 2026Review
- The Immunological Intersection of Psoriasis and Autoimmune Diseases: Shared Pathways and Clinical Implications.Life (Basel, Switzerland) · 2026Review
- Leukotrichia: A comprehensive review of follicular depigmentation.The Journal of international medical research · 2026Review
- Mechanistic Insights into Phytocompounds for Vitiligo Therapy: Current Evidence and Future Opportunities.Antioxidants (Basel, Switzerland) · 2026Review
- Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo.Dermatology and therapy · 2026Article
- Segmental Vitiligo and Somatic Mosaicism: From Pathogenesis to Therapeutics.Annals of dermatology · 2026Review
- IL-21 rs2055979 and serum IL-21 levels are associated with both non-segmental and segmental vitiligo in an Iranian cohort.BMC immunology · 2026Article
- Quality of life impairment in vitiligo: A comprehensive review of psychosocial and clinical determinants.The Journal of international medical research · 2026Review
- Review
- Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
148 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 18 institutions in 12 countries.
Funding
Abstract
During the 2011 International Pigment Cell Conference (IPCC), the Vitiligo European Taskforce (VETF) convened a consensus conference on issues of global importance for vitiligo clinical research. As suggested by an international panel of experts, the conference focused on four topics: classification and nomenclature; definition of stable disease; definition of Koebner's phenomenon (KP); and 'autoimmune vitiligo'. These topics were discussed in seven working groups representing different geographical regions. A consensus emerged that segmental vitiligo be classified separately from all other forms of vitiligo and that the term 'vitiligo' be used as an umbrella term for all non-segmental forms of vitiligo, including 'mixed vitiligo' in which segmental and non-segmental vitiligo are combined and which is considered a subgroup of vitiligo. Further, the conference recommends that disease stability be best assessed based on the stability of individual lesions rather than the overall stability of the disease as the latter is difficult to define precisely and reliably. The conference also endorsed the classification of KP for vitiligo as proposed by the VETF (history based, clinical observation based, or experimentally induced). Lastly, the conference agreed that 'autoimmune vitiligo' should not be used as a separate classification as published evidence indicates that the pathophysiology of all forms of vitiligo likely involves autoimmune or inflammatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.